Early progression in follicular lymphoma in the absence of histological transformation or high‐risk Follicular Lymphoma International Prognostic Index still has a favourable outcome
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early progression in follicular lymphoma in the absence of histological transformation or high‐risk Follicular Lymphoma International Prognostic Index still has a favourable outcome
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-10-20
DOI
10.1111/bjh.18522
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
- (2022) Carla Casulo et al. BLOOD
- The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee
- (2022) Elias Campo et al. BLOOD
- Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma
- (2021) Sara Alonso-Álvarez et al. EUROPEAN JOURNAL OF CANCER
- Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma
- (2020) Connie L. Batlevi et al. EUROPEAN JOURNAL OF CANCER
- Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort
- (2020) Charlotte Madsen et al. LEUKEMIA & LYMPHOMA
- Follicular Lymphoma Evaluation Index ( FLEX ): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy
- (2020) Farheen Mir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population
- (2019) Laura Magnano et al. BRITISH JOURNAL OF HAEMATOLOGY
- Early progression after BR is associated with high risk of transformation in advanced stage follicular lymphoma
- (2019) Ciara L. Freeman et al. BLOOD
- Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era
- (2018) Alfredo Rivas-Delgado et al. BRITISH JOURNAL OF HAEMATOLOGY
- Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
- (2018) John F. Seymour et al. HAEMATOLOGICA
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
- (2016) Matthew J. Maurer et al. AMERICAN JOURNAL OF HEMATOLOGY
- On standardized relative survival
- (2016) Peter Sasieni et al. BIOMETRICS
- Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
- (2016) V. Jurinovic et al. BLOOD
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
- (2015) Carla Casulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
- (2009) Massimo Federico et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started